See how connected MedTech exposure becomes a clearer executive decision.
Five anonymized examples showing how regulatory, clinical, quality, portfolio, and commercial signals were brought into one defensible decision picture.
These examples draw from Dr. Shola Sulaimon’s prior MedTech leadership and advisory experience. Company, product, timing, and operational details have been generalized to protect confidentiality.
The technical issue is only the starting point.
These examples show how SHOTUNE examines the decision under pressure, the connected exposure, the evidence and functions involved, the consequences leadership must consider, and the action required to move forward with a more defensible position.
01
Building One Decision Picture Before Staggered EU Market-Access Decisions
How evidence maturity, resource capacity, certification timing, and commercial exposure were brought together so leadership could evaluate a mixed portfolio as one connected decision.
What changed: Leadership gained one portfolio-level operating view, resourcing and sequencing could be tied to current evidence maturity, and commercial exposure became visible earlier in the decision cycle.
02
Closing a Notified Body Deficiency Response Without Creating New Inconsistencies
How the CER, PMCF, PMS, risk-management file, SSCP, claims, and technical documentation were examined as one response position instead of separate corrective tasks.
What changed: The team moved from isolated document responses to one integrated closure strategy, with clearer distinction between document remediation and wider evidence-system exposure.
03
Finding Commercialization Risk Inside a Clinical Evidence Position
How the evidence position was pressure-tested against intended purpose, claims, regulatory pathway, timing, and commercial commitments before additional investment moved forward.
What changed: Leadership gained a more realistic view of timing, claims, and revenue exposure, shifting the discussion from document completion to whether the evidence could defend the business plan.
04
Turning PMCF Into a Portfolio and Commercialization Tool
How PMCF activities were connected to defined uncertainty, leadership decisions, success criteria, and future certification needs rather than treated as isolated obligations.
What changed: PMCF became more decision-useful, leadership gained clearer visibility into unresolved evidence exposure, and portfolio teams could distinguish valuable evidence activity from activity with weak decision value.
05
Rebuilding Clinical Evaluation Logic Under Current EU MDR Expectations
How long market history, current claims, state of the art, PMS, PMCF, and risk conclusions were tested to determine whether the evidence architecture remained supportable.
What changed: Leadership gained a clearer current view of the legacy evidence position and could prioritize remediation, additional evidence, and product sequencing according to materiality.
Review the decision context behind all five case studies.
The full collection examines the exposure, executive stakes, connected evidence, SHOTUNE decision lens, and recommended point of engagement for each example.
Does one technical issue appear to be creating wider business exposure?
Bring the product, deadline, regulator response, evidence concern, open finding, or portfolio decision. The first conversation will clarify the immediate pressure, the connected exposure, and whether SHOTUNE is the right fit to help.